Moreover, n-3 PUFA significantly decreased MMP-9 levels in relapsing-remitting MS (RR-MS) [97], and other few clinical trials indicate that n-3 PUFA may represent a good complementary treatment in the course of MS [98, 99]. This evidence concerns the gene MMP9 and myeloid sarcoma.